HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Top 10 HIV Clinical Developments of 2016

    In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

    02 December 2016 | The Body Pro
  • UNITAID and ANRS launch initiative in Cameroon to bring new HIV treatments to Africa

    A study launched in Yaoundé will test the latest generation of HIV treatment based on Dolutegravir under local conditions, with a view to establishing its viability in Africa. The results of the study are intended to inform the World Health Organization’s guidelines for the treatment of HIV patients in Africa. If successful, they will help to accelerate the opening of the market for these combinations to manufacturers of generic medicines and thereby reduce prices as well as improve access.

    17 November 2016 | UNITAID
  • Integrase inhibitors associated with improved viral suppression in HIV

    The integrase inhibitor Tivicay combined with low-dose Sustiva was associated with higher rates of long-term viral suppression than standard-dose Sustiva in patients with HIV, data from a network meta-analysis indicated.

    29 September 2016 | Healio
  • Four day a week ART: sub-optimal drug levels but few virological failures

    A poster at IAS 2016 reported on the effectiveness of a strategy in France to use reduced dose maintenance therapy. This involved only taking ART for four rather than seven days a week.

    20 September 2016 | HIV i-Base
  • Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

    I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

    20 September 2016 | BETA blog
  • South Africa ushers in a new era for HIV

    The country has developed the biggest programme of antiretroviral therapy in the world. Now scientists are exploring the long-term consequences of the drugs.

    14 July 2016 | Nature
  • The HIV Treatment Pipeline

    “Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

    28 June 2016 | Poz
  • Antiretrovirals: A Success Story

    Celebrating 20 years of effective HIV treatment - how antiretrovirals have improved since 1996 and the developments we still need.

    28 June 2016 | Poz
  • Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds

    Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small, proof-of-concept study presented at ASM Microbe 2016 in Boston, Massachusetts.

    22 June 2016 | The Body Pro
  • WHO confirms antiretroviral therapy reduces the risk of life-threatening HIV-related infections

    Adults and children with HIV who start antiretroviral therapy (ART) as early as possible reduce their risk of developing serious HIV-related infections, according to new findings published in the journal Clinical Infectious Diseases on 15 June 2016.

    22 June 2016 | World Health Organization
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.